Product Information
XELJANZ 5 MG TABLET is a brand product labeled by Pfizer Inc., priced at $73.7716 per EA under NDC 00069100101. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Nov 6, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Pfizer Inc.NDC
00069100101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TOFACITINIB CITRATEApproval Type
New Drug (NDA)
FDA Application
NDA203214FDA Approved
11/6/2012
TE Code
AB
On Market Since
11/9/2012
Pharmacological Classes
Price Statistics
The NADAC for XELJANZ 5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 121.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $73.7716 per EA |
|---|---|
| All-time high | $98.5905 (Jun 11, 2025) |
| All-time low | $33.2872 (Nov 28, 2013) |
| 52-week high | $98.4538 |
| 52-week low | $73.5726 |
| Median price | $73.7322 |
| Average price | $71.0862 |
| Largest weekly change | -25.0% (Dec 31, 2025) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the tofacitinib market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tofacitinib market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Janus Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XELJANZ 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for XELJANZ 5 MG TABLET, manufactured by Pfizer Inc., is $73.7716 per EA (NDC 00069100101), effective Sep 30, 2026.
How has the price of XELJANZ 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for XELJANZ 5 MG TABLET has risen 121.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for XELJANZ 5 MG TABLET?
Since Nov 28, 2013, the NADAC for XELJANZ 5 MG TABLET has ranged from a low of $33.2872 (Nov 28, 2013) to a high of $98.5905 (Jun 11, 2025), with a median of $73.7322 per EA.
Are there cheaper alternatives to XELJANZ 5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of XELJANZ 5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XELJANZ 5 MG TABLET?
XELJANZ 5 MG TABLET (NDC 00069100101) is labeled by Pfizer Inc., and CMS classifies it as a brand product.